ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0754

Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Zhang, JingJing, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  • Huan, Yonghong, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Leibensperger, Mark R., Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  • Seo, Bojung, University of Indianapolis, Indianapolis, Indiana, United States
  • Song, Yiqing, University of Indianapolis, Indianapolis, Indiana, United States
Background

Previous studies have reported that sodium-glucose co-transporter 2 (SGLT2) inhibitors(SGLT2is) affect serum electrolytes levels, especially magnesium. This study aimed to integrate direct and indirect trial evidence to maximize statistical power to clarify their overall and comparative effects of all SGLT2is on electrolyte levels in patients with type 2 diabetes (T2D).

Methods

We systematically searched PubMed, EMBASE, CENTRAL, and ClinicalTrials.gov up to through January 2021 to identify eligible randomized controlled trials (RCTs) that reported the mean changes in serum electrolytes, including magnesium, sodium, potassium, phosphate, and calcium. We performed both random-effects pairwise and network meta-analyses to calculate the weighted mean difference (WMD) and 95% confidence intervals (CI).

Results

In total, we included 26 RCTs involving 28,943 T2D patients with 6 SGLT2is. Compared with the placebo, SGLT2is were significantly associated with elevations in serum magnesium by 0.7mmol/L (95% CI,0.06, to 0.08 mmol/L) and serum phosphate by 0.02 mmol/L (95% CI, 0.01 to 0.03 mmol/L). Our network meta-analysis showed no evidence of significantly superior efficacy of any specific SGLT2 inhibitor over the others, although dapagliflozin was associated with a larger magnitude in significant increment ases in serum magnesium associated with dapagliflozin (WMD = 0.16 mmol/L), compared to other SGLT2is. Similarly, no statistically detectable differences were evident between any two of SGLT2 inhibitors on serum levels of other electrolytes.

Conclusion

SGLT2is could significantly increased serum magnesium and phosphate levels, consistent with a class effect of SGLT2 inhibition. However, further investigation on more data for long-term efficacy and safety in T2D patients with different clinical phenotypes are needed for further investigation.